Close Menu

NEW YORK (GenomeWeb) – GenMark Diagnostics announced after the close of the market on Tuesday that it has applied to the US Food and Drug Administration for clearance of its ePlex Blood Culture Identification Gram-Negative (BCID-GN) and ePlex Blood Culture Identification Fungal Pathogen (BCID-FP) panels.

As a result, the firm has now completed submissions for all three of its ePlex molecular multiplex panels designed for the diagnosis and management of bloodstream infections that can lead to sepsis. The panels are being developed on GenMark's ePlex sample-to-answer system.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.